Current Report Filing (8-k)
16 August 2022 - 06:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (date of earliest event reported): August 15,
2022
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware
|
001-39990 |
11-3430072
|
|
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
51 Charles Lindbergh Boulevard |
|
|
Uniondale, New York 11553
|
|
|
(Address of principal executive offices, including zip code
)
|
|
(415) 655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
(Title of each class) |
(Trading Symbol) |
(Name of exchange on which registered) |
|
Common Stock |
ANGN |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
o
Item 2.02 Results of Operations and Financial
Condition
On August 15, 2022, Angion Biomedica Corp., a Delaware
corporation (the “Company”), issued a press release announcing the
Company’s financial results for the fiscal quarter ended
June 30, 2022. The press release is furnished as Exhibit 99.1
and is incorporated herein by reference.
The information furnished with this Item 2.02, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
|
|
|
|
|
Exhibit
Number |
|
Exhibit
Description |
|
|
99.1 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL
document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANGION BIOMEDICA CORP. |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ JAY R. VENKATESAN, M.D. |
|
Date: August 15, 2022
|
|
|
|
|
Jay R. Venkatesan, M.D.
President and Chief Executive Officer and Director
|
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Mar 2023 to Apr 2023
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Apr 2022 to Apr 2023
